Filtered By:
Source: Circulation
Condition: Atrial Fibrillation

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 235 results found since Jan 2013.

Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
CONCLUSIONS: Although there was an apparent decrease in relative efficacy to prevent arterial thromboembolism in the upper range of CrCl, the safety and net clinical benefit of HDER compared with warfarin are consistent across the range of renal function. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00781391. PMID: 27358434 [PubMed - in process]
Source: Circulation - July 2, 2016 Category: Cardiology Authors: Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E Tags: Circulation Source Type: research

Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease.
PMID: 27067086 [PubMed - in process]
Source: Circulation - April 11, 2016 Category: Cardiology Authors: Qamar A, Bhatt DL Tags: Circulation Source Type: research

Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated? The CHA2 DS2-VASc 1 Conundrum: Decision Making at the Lower End of the Risk Spectrum.
PMID: 27067085 [PubMed - in process]
Source: Circulation - April 11, 2016 Category: Cardiology Authors: Savino JA, Halperin JL Tags: Circulation Source Type: research

Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated? Yes: Even 1 Stroke Risk Factor Confers a Real Risk of Stroke.
PMID: 27067084 [PubMed - in process]
Source: Circulation - April 11, 2016 Category: Cardiology Authors: Lip GY, Nielsen PB Tags: Circulation Source Type: research

The Use of Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Patients with History of Intra-Cranial Hemorrhage.
CONCLUSIONS: -Warfarin use may be beneficial for AF patients with prior ICH having a CHA2DS2-VASc score ≥6. Whether the use of non-vitamin K antagonist oral anticoagulants (NOACs) could lower the threshold for treatment deserves further study. PMID: 26969761 [PubMed - as supplied by publisher]
Source: Circulation - March 11, 2016 Category: Cardiology Authors: Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Lip GY, Chen SA Tags: Circulation Source Type: research

Risks of Death and Stroke in Patients Undergoing Hemodialysis With New-Onset Atrial Fibrillation: A Competing-Risk Analysis of a Nationwide Cohort.
CONCLUSIONS: -The risk of stroke was only modestly higher in patients undergoing hemodialysis with new-onset AF than in those without AF, and it became insignificant when accounting for the competing risk of in-hospital death. PMID: 26680239 [PubMed - as supplied by publisher]
Source: Circulation - December 17, 2015 Category: Cardiology Authors: Shih CJ, Ou SM, Chao PW, Kuo SC, Lee YJ, Yang CY, Tarng DC, Lin CC, Huang PH, Li SY, Chen YT Tags: Circulation Source Type: research

The Need to Evaluate Net Clinical Effect of Stroke Prevention Therapy in Patients with End Stage Renal Disease and Atrial Fibrillation.
Abstract Chronic kidney disease (CKD) and atrial fibrillation (AF) are both emerging health epidemics worldwide. Atrial fibrillation is the most common heart rhythm disorder and the burden of this dysrhythmia is expected to increase as the population ages(1). Similarly, chronic kidney disease is a disease of the elderly that is estimated to affect 40-50% of US adults over 65 in the near future(2,3). This is likely due to manifestations of common risk factors and pathology that eventually lead to high cardiovascular and stroke risk in patients with CKD, especially patients with AF and CKD(4,5). Unfortunately, the f...
Source: Circulation - December 17, 2015 Category: Cardiology Authors: Patel MR, Piccini JP Tags: Circulation Source Type: research

Polypharmacy and the Efficacy and Safety of Rivaroxaban versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
CONCLUSIONS: -In a population of patients with AF, two-thirds were on ≥5 medications. Increasing medication use was associated with higher risk of bleeding but not stroke. Rivaroxaban was tolerated across complex patients on multiple medications. Clinical Trial Registration Information-ClinicalTrials.gov. Identifier: NCT00403767. PMID: 26673560 [PubMed - as supplied by publisher]
Source: Circulation - December 16, 2015 Category: Cardiology Authors: Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE, Fox KA, Patel MR Tags: Circulation Source Type: research

Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.".
PMID: 26621661 [PubMed - in process]
Source: Circulation - December 1, 2015 Category: Cardiology Authors: Abdul-Rahim AH, Perez AC, Fulton RL, Jhund PS, Latini R, Tognoni G, Wikstrand J, Kjekshus J, Lip GY, Maggioni AP, Tavazzi L, Lees KR, McMurray JJ Tags: Circulation Source Type: research

Letter by Lin et al Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.".
PMID: 26621660 [PubMed - in process]
Source: Circulation - December 1, 2015 Category: Cardiology Authors: Lin GM, Hung Y, Li YH Tags: Circulation Source Type: research

Extracranial Systemic Embolic Events in Patients with Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes.
CONCLUSIONS: -SEE constituted 11.5% of clinically-recognized thromboembolic events in patients with AF and was associated with high morbidity and mortality. SEE mortality was comparable to that of ischemic stroke and varied by anatomic site. PMID: 26224811 [PubMed - as supplied by publisher]
Source: Circulation - July 29, 2015 Category: Cardiology Authors: Bekwelem W, Connolly SJ, Halperin JL, Adabag S, Duval S, Chrolavicius S, Pogue J, Ezekowitz MD, Eikelboom JW, Wallentin LG, Yusuf S, Hirsch AT Tags: Circulation Source Type: research

Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate.
Abstract Atrial disease or myopathy forms the substrate for atrial fibrillation (AF) and underlies the potential for atrial thrombus formation and subsequent stroke. Current diagnostic approaches in patients with AF focus on identifying clinical predictors with the evaluation of left atrial size by echocardiography serving as the sole measure specifically evaluating the atrium. Although the atrial substrate underlying AF is likely developing for years before the onset of AF, there is no current evaluation to identify the preclinical atrial myopathy. Atrial fibrosis is 1 component of the atrial substrate that has g...
Source: Circulation - July 28, 2015 Category: Cardiology Authors: Goldberger JJ, Arora R, Green D, Greenland P, Lee DC, Lloyd-Jones DM, Markl M, Ng J, Shah SJ Tags: Circulation Source Type: research

Apixaban Compared with Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the ARISTOTLE Trial.
CONCLUSIONS: -More than a quarter of the patients in ARISTOTLE with "nonvalvular" atrial fibrillation had moderate or severe valvular heart disease. There was no evidence of a differential effect of apixaban over warfarin in reducing stroke or systemic embolism, causing less bleeding, and reducing death in patients with and without valvular heart disease. Clinical Trial Registration Information-clinicaltrials.gov. Identifier: NCT00412984. PMID: 26106009 [PubMed - as supplied by publisher]
Source: Circulation - June 23, 2015 Category: Cardiology Authors: Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH Tags: Circulation Source Type: research

Restarting Anticoagulant Treatment After Intracranial Haemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality and Bleeding: A Nationwide Cohort Study.
CONCLUSIONS: -Oral anticoagulant treatment was associated with a significant reduction in ischemic stroke/all-cause mortality rates, supporting oral anticoagulant treatment reintroduction post-intracranial haemorrhage as feasible. Future trials are encouraged to guide clinical practice in these patients. PMID: 26059010 [PubMed - as supplied by publisher]
Source: Circulation - June 9, 2015 Category: Cardiology Authors: Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY Tags: Circulation Source Type: research

Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis.
CONCLUSIONS: -DOACs demonstrated at least equal efficacy to VKA in managing thrombotic risks in the elderly however bleeding patterns were distinct. In particular, dabigatran was associated with a higher risk of gastrointestinal bleeding than VKA. Insufficient published data for apixaban, edoxaban and rivaroxaban indicates further work is needed to clarify their bleeding risks in the elderly. PMID: 25995317 [PubMed - as supplied by publisher]
Source: Circulation - May 20, 2015 Category: Cardiology Authors: Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M Tags: Circulation Source Type: research